Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
  1. Home
  2. Blog
  3. Topics
  4. Obesity Trends
Topic

Obesity Trends

6 articles on Obesity Trends, written by Shotlee and medically reviewed for clinical accuracy.

Wegovy for Children: Safety Concerns, Obesity Trends, and Expert Advice
Health & Wellness

Wegovy for Children: Safety Concerns, Obesity Trends, and Expert Advice

An in-depth look at the controversial use of GLP-1 medications in pediatric patients, childhood obesity statistics, and long-term safety concerns highlighted by medical experts.

8 min read
Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?
Health & Wellness

Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?

Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.

8 min read
Expanding Access to GLP-1 Weight-Loss Meds is Essential
GLP-1 Medications

Expanding Access to GLP-1 Weight-Loss Meds is Essential

Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.

5 min read
Denmark's Obesity Rate Stalls in Wegovy-Maker Novo's Home Market
GLP-1 Medications

Denmark's Obesity Rate Stalls in Wegovy-Maker Novo's Home Market

Obesity levels have plateaued in Denmark at 18.5% among adults and older teens in 2025, unchanged from 2021 after years of rises from 13.6% in 2010. Novo Nordisk launched Wegovy there in late 2022, with 270,000 users—nearly 5% of the population—potentially shifting trends away from 32% by 2040 projections. Experts credit GLP-1 drugs like Wegovy and Ozempic alongside lifestyle factors.

4 min read
Obesity Rates Rising to 50% by 2030 Despite GLP-1s: What It Means
Metabolic Health

Obesity Rates Rising to 50% by 2030 Despite GLP-1s: What It Means

Despite the buzz around GLP-1 medications like Wegovy and Zepbound, obesity rates in the U.S. are projected to hit nearly 50% by 2030, per a New England Journal of Medicine study. Severe obesity (BMI 40+) continues to rise, highlighting disparities in food access and demographics. UVA expert Dr. Cate Varney breaks down what this means for public health and patients.

6 min read
GLP-1 Drugs: Slimming Waists and Airlines' Fuel Costs
GLP-1 Medications

GLP-1 Drugs: Slimming Waists and Airlines' Fuel Costs

The GLP-1 drug boom isn't just transforming bodies—it's potentially lightening airplane loads and cutting airline fuel bills. Analysts predict a slimmer society could boost profits, but what's the real story behind these medications? This guide dives into the science, data, and broader implications for your health journey.

4 min read
Browse all blog topics →
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community